Equities analysts predict that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will post earnings of ($0.19) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Arrowhead Pharmaceuticals’ earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.21). Arrowhead Pharmaceuticals posted earnings per share of ($0.07) in the same quarter last year, which would suggest a negative year-over-year growth rate of 171.4%. The company is expected to report its next quarterly earnings report on Thursday, August 2nd.
On average, analysts expect that Arrowhead Pharmaceuticals will report full-year earnings of ($0.74) per share for the current year, with EPS estimates ranging from ($0.78) to ($0.69). For the next year, analysts anticipate that the firm will report earnings of ($0.55) per share, with EPS estimates ranging from ($0.92) to $0.89. Zacks’ EPS calculations are an average based on a survey of research firms that follow Arrowhead Pharmaceuticals.
Get Arrowhead Pharmaceuticals alerts:Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01. Arrowhead Pharmaceuticals had a negative net margin of 199.55% and a negative return on equity of 50.05%. The business had revenue of $0.65 million during the quarter, compared to analyst estimates of $4.04 million.
Several equities research analysts recently issued reports on the stock. BidaskClub raised shares of Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 15th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, May 30th. ValuEngine raised shares of Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Piper Jaffray Companies boosted their target price on shares of Arrowhead Pharmaceuticals to $11.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 8th. Finally, Jefferies Financial Group assumed coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, March 27th. They set a “buy” rating and a $10.00 target price for the company. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $9.45.
In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 20,000 shares of the business’s stock in a transaction on Tuesday, June 19th. The shares were sold at an average price of $14.01, for a total transaction of $280,200.00. Following the completion of the transaction, the chief financial officer now owns 330,815 shares of the company’s stock, valued at approximately $4,634,718.15. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Douglas B. Given sold 25,000 shares of the business’s stock in a transaction on Tuesday, April 24th. The stock was sold at an average price of $6.63, for a total transaction of $165,750.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 79,000 shares of company stock valued at $759,950. Company insiders own 4.60% of the company’s stock.
Several large investors have recently bought and sold shares of ARWR. Schwab Charles Investment Management Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 8.8% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 186,381 shares of the biotechnology company’s stock worth $686,000 after purchasing an additional 15,132 shares during the period. Wells Fargo & Company MN increased its holdings in shares of Arrowhead Pharmaceuticals by 237.3% during the 4th quarter. Wells Fargo & Company MN now owns 69,997 shares of the biotechnology company’s stock worth $257,000 after purchasing an additional 49,246 shares during the period. OppenheimerFunds Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 110.0% during the 4th quarter. OppenheimerFunds Inc. now owns 6,300,000 shares of the biotechnology company’s stock worth $23,184,000 after purchasing an additional 3,300,000 shares during the period. Allianz Asset Management GmbH increased its holdings in shares of Arrowhead Pharmaceuticals by 2.2% during the 4th quarter. Allianz Asset Management GmbH now owns 462,105 shares of the biotechnology company’s stock worth $1,701,000 after purchasing an additional 9,985 shares during the period. Finally, BlueCrest Capital Management Ltd bought a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth about $275,000. Institutional investors own 46.31% of the company’s stock.
ARWR stock opened at $13.26 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 10.16 and a quick ratio of 10.16. Arrowhead Pharmaceuticals has a 1 year low of $1.48 and a 1 year high of $14.24. The firm has a market capitalization of $1.15 billion, a P/E ratio of -28.21 and a beta of 2.57.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
Get a free copy of the Zacks research report on Arrowhead Pharmaceuticals (ARWR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment